Full Press Release Details
Investors can contact the law firm at no cost to learn more about recovering their losses
LOS ANGELES, Aug. 05, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Praxis Precision Medicines, Inc. (“Praxis” or “the Company”) (NASDAQ: PRAX) investors that the firm has initiated an investigation into possible securities fraud and may file a class action on behalf of investors. Praxis investors that lost money on their investment are encouraged to contact Lesley Portnoy, Esq.
Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: info@portnoylaw.com, to discuss their legal rights, or click here to join the case. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors’ options for pursuing claims to recover their losses.
On August 4, 2025, Praxis Precision Medicines, Inc. issued a press release announcing its financial results for the second quarter of 2025. In addition to its financial disclosures, the Company reported mid-stage clinical trial results for its anti-seizure medication, vormatrigine. Praxis disclosed that 36 of 61 patients experienced treatment-emergent adverse events, and nearly 25% of study participants discontinued participation.
Following this announcement, Praxis’s stock price declined by $3.00 per share, or approximately 5.55%, closing at $51.09 per share on August 4, 2025.
Please visit our website to review more information and submit your transaction information.
The Portnoy Law Firm represents investors in pursuing claims against caused by corporate wrongdoing. The Firm’s founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes.
Lesley F. Portnoy, Esq.
Admitted CA, NY and TX Bars
Attorney Advertising